ML-60218 是一种广谱 RNA pol III 抑制剂，对酿酒酵母和人类 RNA pol III 的 IC₅₀ 分别为 32 和 27 μM。ML-60218 破坏已经组装好的病毒体，并且在不需要重新转录细胞 RNA 的情况下阻碍新病毒体的形成。

ML-60218 is a broad-spectrum RNA pol III inhibitor, with IC 50 s of 32 and 27 μM for Saccharomyces cerevisiae and human. ML-60218 disrupts already assembled viroplasms and to hamper the formation of new ones without the need for de novo transcription of cellular RNAs.

Liquid

Combination of SAHA and ML-60218 produces enhanced suppression of proliferation in human pancreatic adenocarcinoma by impairing cell cycle progression and inducing apoptosis. ML-60218 reverses SAHA-stimulated tRNA expression in PANC-1 and BxPC-3 cells. ML-60218 enhances the ability of HDAC inhibitors to induce apoptosis and cell cycle arrest.
In in vitro transcription assays with purified double-layered particles (DLPs), ML-60218 shows dose-dependent inhibitory activity, indicating the viral nature of its target. ML-60218 is found to interfere with the formation of higher-order structures of VP6, the protein forming the DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-60218-treated DLPs shows dose-dependent structural damage. ML-60218-mediated (10 μM ) viroplasm disruption causes NSP5 dephosphorylation.

Room temperature in continental US; may vary elsewhere.

Pure form -20°C 3 years；4°C 2 years

[1]. Wu L, et al. Novel small-molecule inhibitors of RNA polymerase III. Eukaryot Cell. 2003;2(2):256-264.
[2]. Yee NS, et al. Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer. Biol Open. 2012;1(4):295-307.
[3]. Eichwald C, et al. Identification o

In Vitro: DMSO : 100 mg/mL (221.05 mM; Need ultrasonic)配制储备液